Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Generalized Anxiety Disorder
Conditions
Generalized Anxiety Disorder
Trial Timeline
Aug 18, 2021 → Aug 24, 2021
NCT ID
NCT04965272About Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day is a phase 2 stage product being developed by AbbVie for Generalized Anxiety Disorder. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04965272. Target conditions include Generalized Anxiety Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04965272 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Generalized Anxiety Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 65 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Perampanel + Placebo comparator | Eisai | Phase 3 | 77 |
| zonisamide | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Cenobamate | Ono Pharmaceutical | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Approved | 85 |
| Ixekizumab | Eli Lilly | Approved | 85 |
| eszopiclone + eszopiclone + Placebo | Sumitomo Pharma | Phase 2 | 52 |
| Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment | Sumitomo Pharma | Approved | 85 |
| ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT) | AbbVie | Phase 2 | 52 |
| ABBV-932 + Placebo | AbbVie | Phase 1 | 33 |
| Escitalopram | AbbVie | Approved | 85 |
| Adalimumab | AbbVie | Phase 3 | 77 |
| Quetiapine fumarate + Paroxetine | AstraZeneca | Phase 3 | 77 |